Gastric and Fluorouracil


Gastric Symptoms and Causes

Your stomach is an organ between your esophagus and small intestine. It is where digestion of protein begins. The stomach has three tasks. It stores swallowed food. It mixes the food with stomach acids. Then it sends the mixture on to the small intestine.

Most people have a problem with their stomach at one time or another. Indigestion and heartburn are common problems. You can relieve some stomach problems with over-the-counter medicines and lifestyle changes, such as avoiding fatty foods or eating more slowly. Other problems like peptic ulcers or GERD require medical attention.

You should see a doctor if you have any of the following:

  • Blood when you have a bowel movement
  • Severe abdominal pain
  • Heartburn not relieved by antacids
  • Unintended weight loss
  • Ongoing vomiting or diarrhea

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Check out the latest treatments for gastric

gastric treatment research studies

Fluorouracil clinical trials, surveys and public health registries

Find Drug Side Effect reports

Fluorouracil Side Effects

Diarrhoea (463)
Nausea (335)
Dehydration (273)
Vomiting (266)
Neutropenia (243)
Febrile Neutropenia (207)
Pyrexia (187)
Mucosal Inflammation (179)
Asthenia (158)
Abdominal Pain (152)
Stomatitis (143)
Fatigue (134)
Dyspnoea (131)
Interstitial Lung Disease (117)
Decreased Appetite (116)
Pulmonary Embolism (111)
Chest Pain (110)
Anaemia (106)
Thrombocytopenia (106)
Hypotension (106)
Neutrophil Count Decreased (99)
Hypokalaemia (95)
Leukopenia (83)
Sepsis (78)
White Blood Cell Count Decreased (78)
Renal Failure Acute (75)
Pneumonia (75)
Malaise (74)
Haemoglobin Decreased (72)
Neuropathy Peripheral (69)
Pain (69)
Renal Failure (64)
Disease Progression (64)
Respiratory Failure (62)
Cardiotoxicity (62)
Dysphagia (61)
Confusional State (57)
Platelet Count Decreased (57)
Pancytopenia (55)
Fall (55)
Deep Vein Thrombosis (54)
Myocardial Infarction (53)
Arteriospasm Coronary (51)
Hyponatraemia (51)
Weight Decreased (51)
Tachycardia (48)
Chills (46)
Dizziness (46)
Septic Shock (46)
Hyperammonaemia (46)

➢ More

Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)

Recent Reviews

Why do doctors keep the availabilty of the test for DPD deficiency a secret??? My sister is a doctor, infectious disease, at St Francis in Charleston, SC. Our father was treated by an oncologist well known to my sister, a 'colleague' you might s

Constant lower abdomen ,nausea,headaches,loss of appetite

Its not 1%---more like 14% and that may even be a conservative estimate--Your doctor is lieing to you--surprised???

Microscopic examination. sections show esophageal squamus epithelium and gastric mucosa. There is a mild lymphocytic infiltrate. There is a mild eosinophilic infiltrate.

My fiancee passed away on 3/7/2011 after her second round of 5FU. The oncologist had used the words 'surprised' and 'out of the ordinary' on her reaction to the first round because of the amount and severity of her side effects. H

Nesecito hacer un mapa conceptual acerca de las infeciccion gastrica

After taking clonidine 0.1mg cut 9in half, for two dauys, twicw a day: it felt like a I had a terrible gastric ulcer. i TOOK IYT WITH A MEAL AND DRANK 10 OUNCES OF WATER. i took it again the next day with the same result. Do they

Got instant relief using this, but suffered from many other side effects, likegastricproblems, blood dilution, pain in heart (diagnosis on going)

Hi! Some years ago I took nexium for v. severe gerd, with haemorrhage. From the time I started it, suddenly my gastric system was totally upset, where it hadn't previously. Because I wasn't digesting properly, my immune system was affected, and hav

Hi, i sufer from gastric ulcer and im treated with colofac and pantoprazole and after abaute 3days of using these drugs i experienced the diarrhoea and i had it for 2 weeks. so i left using colofac and every thing was going good for 2days, but after

I am 30 year old female. I have painful blister at the anal region. I was prescribed etoricoxib thiocolchicoside as a pain killer. I have been experiencing burning abdominal burning sensation and gastric problems.

I am 7 years post-op for gastric bypass. I suddenly started frequent nausea. Then sttarted waking up from a sound sleep nauseated and dry heaving. I dry heave so much at time I have stomach spasms. What could this be a sign of? Is my surgery messed u

I am also experiencig these symptoms particularly gastric problems

I am now 37 and have been on epilim for the past 19 years. I stuggle alot with my weight and have even considered a gastric bypass but after doing some research found out that people who suffered from epilepsy who had the operatin only got worse so d

I am taking 80mg of frusemide for intercranial hypertension,its my last hope before surgury. I have been on it for 3 weeks and am feeling lightheaded,nauseas.gastric upset,unable to eat properly and have an increase in depression. im going to cut dow

I am taking Ciprobay for 5 days and when the second day passed I was suffering full of Gastric

Gastric Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting Gastric Partitioning Procedure for the Treatment of Unresectable and Obstructive Distal Gastric Cancer
Condition: Gastric Cancer
Interventions: Procedure: Gastro-entero anastomosis only;   Procedure: Gastric partitioning Plus Gastro-entero anastomosis
Outcome Measures: Change from baseline Gastric Outlet Obstruction Score System - GOOSS;   Overall survival
2 Recruiting Screening for Gastric Cancer in High-risk Population
Condition: Gastric Cancer
Outcome Measures: Characterization of the high-rik individual for Gastric cancer - "Gastric Cancer Phenotype";   Establish a screen plan for high-risk population for Gastric cancer
3 Unknown  Banded Versus Non-banded Roux-en-Y Gastric Bypass
Condition: Morbid Obesity
Intervention: Procedure: Gastric bypass
Outcome Measures: Excessive Weight Loss;   pouch dilatation, band migration, reflux, esophageal motility
4 Recruiting Early Onset and Familial Gastric Cancer Registry
Condition: Gastric Cancer
Intervention: Behavioral: questionnaires
Outcome Measures: Create registry of families w/ early onset & familial Gastric cancer for analysis of risk factors, family history and unidentified susceptibility genes. Create cohorts of pts w/ low genetic risk for the development of Gastric cancer;   To determine the incidence of CDH1 germline mutations among individuals with early onset or familial Gastric cancer and their relatives.;   To determine the Gastric pathology evident from a single baseline endoscopic screen of unaffected first-degree relatives of a patient with EOGC or FGC.
5 Recruiting The Optimal Width of Gastric Conduit for Minimally Invasive Esophagectomy: Wide or Narrow?
Condition: Anastomotic Leakage
Interventions: Procedure: Narrowed Gastric Conduit;   Procedure: Widened Gastric Conduit
Outcome Measure: The anastomotic leakage rate
6 Recruiting Screening for Familial Gastric Cancer in First Degree Relatives
Conditions: Malignant Neoplasm of Stomach;   Carcinoma, Diffuse Type;   Intestinal Type Adenocarcinoma of Stomach;   Relative (Related Person)
Intervention: Other: Endoscopy with staining of the mucosa
Outcome Measures: The percentage of increasement of endoscopic detection of (pre)malignant for Gastric cancer by staining of the Gastric mucosa.;   To determine the optimal pathological work-up the detection rate of (pre-)malignancy, measured by the number of (pre) malignant foci found by the pathologist with different coloring and immunohistochemic techniques.;   To determine the association of clinical and life style factors with the two type of Familial Gastric Cancer, partly assessed from the patients'clinical files (eg BMI), partly by assessment of possible risk factors in blood (eg Helicobacter Pylori).;   To determine the psychosocial impact of the screening protocol in this population, measured as the amount of stress and anxiety by use of the Hospital Anxiety and Distress Scale and the amount of cancer-worry by use of the Cancer Worry Scale.
7 Recruiting An Effect of an Individualized Physical Activity Intervention for Gastric Cancer Patient Undergoing Minimally Invasive Gastrectomy: a Phase III, Prospective Randomized Controlled Trial
Condition: Gastric Cancer
Intervention: Behavioral: physical activity intervention
Outcome Measures: QoL(quality of life);   result of blood sample test;   cardiopulmonary function test;   vital signs reflecting of inflammation level;   nutrition condition
8 Recruiting Trial of Preoperative Therapy for Gastric and EsophagoGastric Junction Adenocarcinoma
Condition: Gastric Cancer
Interventions: Drug: Epirubicin + cisplatin + 5-fluorouracil;   Radiation: Preoperative chemoradiotherapy;   Procedure: Gastric resection
Outcome Measures: Overall survival;   Disease free survival;   Pathological response rate;   Proportion of participants with given grades of toxicities;   Surgical complete resection rate (R0)
9 Recruiting Dermabond Treatment for Gastric Variceal Bleeding
Condition: Gastric Varices
Intervention: Procedure: DermaBond treatment of Gastric Varices
Outcome Measure: To determine the clinical impact of endoscopic ultrasound treatment of Gastric variceal bleeding.
10 Recruiting Long or Very Long-Limb Gastric Bypass in Superobese
Condition: Obesity
Intervention: Procedure: laparoscopic Gastric Roux-en-Y Gastric bypass
Outcome Measures: weight loss- we will compare percentage of excess body weight loss (%EWL) between groups.;   To compare body mass index changes and absolute weight loss. To evaluate obesity-related medical problems. To obtain data about impromvement of metabolic syndrom. To compare quality of life changes between treatment arms.
11 Unknown  Roux-en-Y Versus Billroth II Reconstruction After Subtotal Gastrectomy in Gastric Cancer Comorbid With Type II Diabetes
Conditions: Gastric Cancer;   Type 2 Diabetes
Intervention: Procedure: Stomach-small intestine reconstruction
Outcome Measures: Glycemic control;   Nutritional status assessment
12 Unknown  A Prospective Randomized Controlled Multicenter Trial of Delayed Gastric Emptying (DGE) After Pancreaticoduodenectomy Evaluating by Gastrointestinal Reconstruction
Condition: Postprocedural Delayed Gastric Emptying
Interventions: Procedure: Retrocolic gastro- or duodeno- jejunostomy in hte pancreaticoduodenectomy;   Procedure: Antecolic gastro- or duodeno- jejunostomy in the pancreaticoduodenectomy
Outcome Measure: Incident rate of delayed Gastric emptying
13 Recruiting Circulating Exosomes As Potential Prognostic And Predictive Biomarkers In Advanced Gastric Cancer Patients ("EXO-PPP Study")
Condition: Gastric Cancer
Outcome Measures: • Characterization of the molecular profile in tumor derived exosomes from advanced Gastric cancer patients undergoing first-line chemotherapy;   • Correlation of plasma level and kinetics of Gastric cancer derived exosomes (at baseline and monthly during therapy until tumor progression or death) and time-to-event end-points: Overall survival, Progression-free survival and Overall response rate.
14 Recruiting Silastic Ring Gastric Bypass Versus Sleeve Gastrectomy for Type 2 Diabetes Mellitus in Obese Patients
Conditions: Type 2 Diabetes Mellitus;   Obesity
Interventions: Procedure: Laparoscopic Silastic Ring Roux-en-Y Gastric Bypass;   Procedure: Laparoscopic Sleeve gastrectomy
Outcome Measures: Remission of type 2 diabetes mellitus;   Weight loss (excess weight loss and actual weight loss);   Comorbidity resolution;   Peri/ post-operative morbidity and mortality;   Changes in body composition, resting energy expenditure and bone density;   Quality of Life
15 Not yet recruiting Confocal Laser Endomicroscopy for the Diagnosis of Gastric Intestinal Metaplasia, Intraepithelial Neoplasia, and Carcinoma
Conditions: Gastric Intestinal Metaplasia;   Gastric Intraepithelial Neoplasia;   Gastric Carcinoma
Interventions: Device: Confocal laser endomicroscopy (Pentax, EG3870K);   Device: Standard White-light endoscopy (Pentax, 90i)
Outcome Measures: number of participant with Gastric IM/IN/CA;   number of biopsies needed per patient
16 Recruiting A Study Comparing Billroth II With Roux-en-Y Reconstruction for Gastric Cancer
Conditions: Gastric Cancer;   Stomach Cancer;   Gastrectomy
Intervention: Procedure: Roux-en-Y or Billroth II
Outcome Measures: The aim of this study is to compare Billroth II and Roux En Y reconstruction after radical distal subtotal gastrectomy for Gastric cancer in terms of postoperative outcomes.;   Quality of life pre and post operatively will be compared between Billroth II and Roux En Y reconstruction after radical distal subtotal gastrectomy.;   Gastrointestinal symptoms assessment;   Assessing nutritional status;   Grading of gastritis and/or esophagitis on endoscopy
17 Recruiting Multicentric Randomized Study of H. Pylori Eradication and Pepsinogen Testing for Prevention of Gastric Cancer Mortality
Conditions: Helicobacter Pylori Infections;   Atrophic Gastritis;   Gastric Cancer
Intervention: Drug: Triple therapy
Outcome Measures: Gastric cancer mortality;   Gastric cancer incidence;   All-cause mortality;   Incidence of- and mortality from other medical conditions
18 Recruiting Postoperative IMRT Combined With Capecitabine for Advanced Gastric Cancer Patients
Condition: Gastric Cancer
Intervention: Radiation: concurrent chemoradiation
Outcome Measures: feasibility of concurrent IMRT combined with capecitabine for the treatment of Gastric cancer patients;   efficacy of concurrent IMRT combined with capecitabine for the treatment of Gastric cancer patients
19 Recruiting Gastric Cancer Prevention in the Family Members by Helicobacter Pylori Eradication
Conditions: Gastric Cancer;   Bacterial Infection Due to Helicobacter Pylori (H. Pylori)
Interventions: Drug: Placebo;   Drug: LAC triple therapy
Outcome Measure: Gastric cancer incidence
20 Recruiting Randomized Controlled Trial to Prevent Peritoneal Seeding in Gastric Cancer
Conditions: Gastric Cancer;   Peritoneal Carcinomatosis
Interventions: Drug: HIPEC with mytomycin and cisplatin;   Procedure: Diagnostic laparoscopy one year after gastrectomy
Outcome Measures: Peritoneal carcinosis free survival;   Disease free Survival